| This week's sponsor is Premier Research. | | | New Insights in the Battle Against Alzheimer’s
Thanks to awareness efforts like World Alzheimer’s Day this Friday, there’s a relentless focus on finding breakthrough therapies for this ravaging disease. Our new white paper looks at how we’re combating this growing epidemic. Premier Research. It’s what we do. Best. |
Today's Rundown Amicus joins gene therapy surge with $100M pipeline purchase Kymera taps former Alnylam executive Jared Gollob as CMO 3 international charities to fund £30M post-Brexit cancer research model [Sponsored] Six Practices of High Performing Clinical Research Sites Corbus nets over 600 endocannabinoid-related compounds, planning to develop 1-2 per year Trial takes FibroGen’s renal anemia drug closer to EU filing Tvardi Therapeutics raises $9M series A for STAT3 inhibitors Exicure plans checkpoint combo after TLR9 drug clears early test Featured Story | | | Thursday, September 20, 2018 Amicus Therapeutics has paid $100 million to buy Celenex. The takeover gives Amicus a ready-made pipeline of 10 gene therapies, including two that are in clinical trials. |
|
|
Top Stories Thursday, September 20, 2018 Jared Gollob, M.D., who headed up clinical development and medical affairs at Alnylam Pharmaceuticals, is joining Kymera Therapeutics, a startup focused on protein degradation. Wednesday, September 19, 2018 Three major international cancer charities plan to invest about £30 million ($39.4 million) into six U.K. and European research projects, in a bid to provide a collaboration model for an uncertain post-Brexit world. Monday, September 17, 2018 Clinical research sites have a tough, but critically important, job. It’s rigorous and precise work, but essential to the progress of medicine. Thursday, September 20, 2018 Corbus Pharmaceuticals Holdings has licensed worldwide rights to drug candidates from more than 600 compounds targeting the endocannabinoid system from Jenrin Discovery—which it says will fuel one to two new clinical programs in inflammatory and fibrotic diseases each year, starting in 2020. Thursday, September 20, 2018 FibroGen’s partner Astellas has reported phase 3 data that could support filings of their HIF inhibitor in Europe as an oral alternative to EPO drugs. Thursday, September 20, 2018 Tvardi Therapeutics will finish a phase 1 trial of its lead asset, an oral STAT3 inhibitor, in solid tumors and start multiple proof-of-concept studies in additional cancer indications. Thursday, September 20, 2018 Exicure is set to move toll-like receptor 9 (TLR9) agonist AST-008 into a phase 1b/2 trial after getting a look at data from healthy volunteers. The first-in-human clinical trial suggested that AST-008 is safe, tolerable and boosts cytokine levels. | This week's sponsor is the Fierce Innovation Awards – Life Sciences Edition. | | | |
Resources Sponsored by: Amazon Web Services Download our new eBook to learn how Healthcare and Life Sciences organizations are taking advantage of solutions from AWS and the AWS Partner Network to obtain value from critical data. Sponsored by: Veeva A top 20 pharma and growing biotech re-engineer regulatory processes. Sponsored by: Covance FSPx Covance FSPx boasts one of the world’s largest dedicated FSP groups in the contract research organization space with ~4200 staff in 60+ countries. Sponsored by: Sciformix Are automation, big data and artificial intelligence (AI) a key part of your company’s pharmacovigilance strategy? Read this whitepaper to know what they should be! Sponsored by: Covance FSPx Covance FSPx boasts one of the world’s largest dedicated FSP groups in the contract research organization space with ~4200 staff in 60+ countries. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Sponsored by: Patheon, part of Thermo Fisher Scientific When developing a parenteral, pharmaceutical scientists are faced with a variety of choices – choices that can be conflicting or present differing advantages. Sponsored by: Baxter Baxter BioPharma Solutions’ whitepaper offers a method to address the challenges of tech transfer for lyophilized products from lab-scale to commercial-scale. Sponsored by: Blue Matter A whitepaper outlining the key commercial challenges facing rare disease products, and how biopharmaceutical companies can overcome them. Sponsored by: AWS and Tableau Inova is using the capabilities of Tableau on AWS to identify biomarkers for personalized treatment intended to improve health outcomes for children. Sponsored by: AWS and Reltio Reltio and IQVIA provide holistic data management solutions for traditional pharma, emerging biotech, and consumer health companies, on AWS. Presented by: AWS and Druva Life Sciences organizations are embracing cloud-based Master Data Management (MDM) to modernize the organization of critical data. Sponsored by: Health Strategies Group The window of market exclusivity continues to narrow dramatically in the global marketplace. Given this demanding environment, your global market access team faces increasing urgency to get the value proposition right at the time of launch. Sponsored by: PharmaCord When was the last time your patient support program perfectly aligned with the patient journey, solving all the critical gaps in positioning your brand for success? Follow the 3-D approach to your solution design, and you will achieve a better outcome for your patients. Sponsored by: Catalent Develop a basic understanding of principles and concepts of bioavailability of oral drugs. Drug Approval, Manufacturing Quality & Regulation 2018 | Online Drug Development Boot Camp® 2018 – Registration closes 30 October - Register Now! November 14-15, 2018 | Boston, MA | Registration closes on the 30 of October 2018 due to the need for participants to complete pre-Boot Camp preparations. Register now and start preparing for this intensive training in drug development. AI World Conference and Expo 2018 Monday, December 3, 2018 | 10/5/18 – Early Deadline 2018 Latin America Healthcare Compliance Certification Program September 24-27, 2018 | Sao Paulo, Brazil FierceBiotech 3rd Drug Development Forum October 1–3, 2018 | Hilton Boston Logan Airport Hotel | Boston, MA Compliance Certification Program at Seton Hall Law October 8-11, 2018 | Newark, NJ BioImmersion: Biotech for the Non-Scientist October 16-18, 2018 | Chicago, IL Fierce Innovation Awards: Life Sciences Edition 2018 Welcome to the inaugural Neuromuscular Drug Development Summit October 29-31, 2018 | Boston, MA, USA FierceBiotech Executive Summit: London October 30, 2018 | Royal Society of Medicine Understanding Commercialization Within Biopharma Nov 7-8, 2018 | Boston, MA Drug Development Immersion December 5-6, 2018 | San Diego, CA Understanding Drug Pricing and Reimbursement December 12, 2018 | Boston, MA | 